Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaCT in Localized TNBC
NCT02593175Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2016
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2016; status: completed.
02
Drugs
panitumumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02593175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593175.